The addition of nivolumab to trimodality therapy may improve relapse-free survival in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), according to results of a phase 2 randomized study by the Hellenic GU Cancer Group. Results are presented at the European Society for Medical Oncology Congress 2024. ...
Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
The AMBASSADOR study demonstrated a significant improvement in disease-free survival for pembrolizumab.
Dr. Plimack provides an update on the SWOG S1314 trial for MIBC, including four genes predictive of pT0 disease after NAC.
Immunotherapy is often used for metastatic disease, yet it is still under investigation in neoadjuvant and adjuvant settings.
Dr. Brad McGregor shares exciting developments in the MIBC space and the challenges facing the field of GU oncology.
In patients with MIBC, any tumors with ATM, RB1, FANCC, or ERCC2 mutations were likely to respond to treatment with NAC.
Researchers evaluated the data of 50 specimens from patients who underwent TURBT and cystectomy for UC.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Disitamab vedotin plus pembrolizumab shows promising efficacy, manageable safety in HER2+ aUC, with a 61.1% response rate.
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
PFS was improved with nivolumab plus cabozantinib.
In patients with pretreated UC, BL-B01D1 demonstrated manageable safety with encouraging antitumor activity.
Enfortumab vedotin plus pembrolizumab showed consistent PFS and OS benefit across all subgroups.
The AMBASSADOR study demonstrated a significant improvement in disease-free survival for pembrolizumab.
Advertisement
Section Editor
Brad McGregor, MDGenitourinary Medical Oncologist | Dana-Farber Cancer Institute
Advertisement
Get the latest bladder cancer research straight to your inbox.
